{"a":[{"_":"PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry market","$":{"href":"/biotech/ptcs-211m-bid-wins-sangamo-auction-teeing-special-opportunity-enter-fabry-market","hreflang":"en"}}]}

Positive

AI Analysis

Summary

PTC Therapeutics won a competitive auction to acquire Sangamo Therapeutics' near-approval Fabry disease gene therapy program for $111 million upfront, while Sangamo also sold technology to Eli Lilly for $50 million as part of its bankruptcy proceedings.

Outcome Details

PTC Therapeutics acquired Sangamo Therapeutics' Fabry disease gene therapy program for $111 million upfront

Importance:7/10

Sentiment:

0.60

M&Abankruptcygene therapyFabry diseaseasset sale

Related Companies

$SGMOQ $LLY $ALPMY

Read the original article

Published by FierceBiotech on August 13, 2026 8:16 AM

Read Original